Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Stevanato Group SpA's share price for the quarter that ended in Dec. 2024 was €20.4. Stevanato Group SpA's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 273 Mil. Therefore, Stevanato Group SpA's market cap for the quarter that ended in Dec. 2024 was €5,567 Mil.
Stevanato Group SpA's quarterly market cap
increased
from Jun. 2024 (€4,584 Mil) to Sep. 2024 (€4,830 Mil) and
increased
from Sep. 2024 (€4,830 Mil) to Dec. 2024 (€5,567 Mil).
Stevanato Group SpA's annual market cap
increased
from Dec. 2022 (€4,500 Mil) to Dec. 2023 (€6,530 Mil) but then
declined
from Dec. 2023 (€6,530 Mil) to Dec. 2024 (€5,567 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Stevanato Group SpA's Enterprise Value for Today is €5,358 Mil.
Stevanato Group SpA Market Cap Historical Data
The historical data trend for Stevanato Group SpA's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Stevanato Group SpA's Market Cap
For the Medical Instruments & Supplies subindustry, Stevanato Group SpA's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stevanato Group SpA's Market Cap Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stevanato Group SpA's Market Cap distribution charts can be found below:
* The bar in red indicates where Stevanato Group SpA's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Stevanato Group SpA's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stevanato Group SpA (FRA:87N) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Stevanato Group SpA Market Cap Related Terms
Thank you for viewing the detailed overview of Stevanato Group SpA's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:87N has been successfully added to your 